News Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
27.21 ^USD	-0.40%		+3.34%	-19.35%

Mar. 13	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
Mar. 13	Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024	Apr. 30	GL
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	Mar. 20	AQ
Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	Mar. 13	MT
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	Mar. 13	DJ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	GL
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	AQ
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	Mar. 13	CI
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	Mar. 08	MT
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	Mar. 06	GL
RBC Cuts Price Target on Pacira BioSciences to $45 From $53, Keeps Outperform Rating	Mar. 01	MT
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	Feb. 29	MT
Transcript : Pacira BioSciences, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Pacira: Q4 Earnings Snapshot	Feb. 29	AQ
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	Feb. 29	CI
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	Feb. 29	CI
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	Feb. 29	MT
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	Feb. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Summary

Filters